<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      PE
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/pe" data-history-node-id="1041" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
        <p style="border:none; padding:0in">
         <span style="font-size:11pt">
          <span style="line-height:107%">
           <span style="font-family:Calibri,sans-serif">
            <b>
             <span style="font-size:12.0pt">
              <span style="line-height:107%">
               <span style="font-family:Palatino">
                Pulmonary Embolism – Nick Pietrini
               </span>
              </span>
             </span>
            </b>
           </span>
          </span>
         </span>
        </p>
       </div>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="line-height:107%">
             <span style="font-family:Palatino">
              Background
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               A thrombus or “clot” originating in a deep vein (LE > UE) embolizing to the pulmonary arterial circulation
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Virchow’s
              </span>
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              triad: stasis (immobilization, travel), hypercoagulable state (cancer), injury to endothelium (surgery, trauma). Idiopathic possible but 12% of idiopathic will be diagnosed with cancer within a year.
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Genetic
              </span>
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              : Factor V Leiden, prothrombin gene mutation, protein C/S deficiency, antithrombin III deficiency
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Acquired
                </span>
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                : antiphospholipid syndrome, cancer, myeloproliferative disorders, nephrotic syndrome, OCPs
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Classification (requires TTE):
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Low risk:
                 </span>
                </span>
               </span>
              </b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Hemodynamically Stable without RV strain or myocardial necrosis
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Submassive:
                 </span>
                </span>
               </span>
              </b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Hemodynamically stable with RV strain and/or myocardial necrosis
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li style="list-style-type:none">
             <ul style="list-style-type:disc">
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    RV strain seen on TTE (“D-sign”), BNP >150
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Myocardial necrosis with troponin >0.05
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
             </ul>
            </li>
           </ul>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Massive:
                 </span>
                </span>
               </span>
              </b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Sustained hypotension and/or concerns for shock
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
       </ul>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="line-height:107%">
             <span style="font-family:Palatino">
              Presentation
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Dyspnea / Tachypnea – most common, can be only exertional
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Tachycardia – common, sometimes the only finding
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Chest pain – usually pleuritic
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Hemoptysis
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Lower extremity pain / swelling – occurs in 50% of pts with DVT
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              RV Failure (large PE) – elevated JVP, hypotension, syncope
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="line-height:107%">
             <span style="font-family:Palatino">
              Evaluation
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              EKG: most commonly sinus tachycardia
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Less
                </span>
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                commonly and indicative of large PE: Right axis deviation, RVH, RBBB, RA enlargement, S1Q3T3 (deep S in lead I, deep Q and inverted T in lead III), TWI in V1-V3 (most common finding reflecting severity)
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              CXR (typically normal)
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Subtle
              </span>
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              abnormalities: linear atelectasis, pleural effusion, PA cutoff sign
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              ABG: usually with hypoxia, hypocapnia, high A-a gradient
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Troponin: increases in 30-50% of pts with moderate to large PE associated with RV strain
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              BNP: often increases with large PE (but less so than in HF patients)
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              D-Dimer*: If low pre-test probability (based on Wells criteria)
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              CTA Chest PE protocol; NPV 95-99%
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Helps
                </span>
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                identify potential alternative diagnoses as well as determine severity of PE
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              V/Q scan: Useful when CXR is normal, no severe cardiopulmonary abnormalities, and contraindication to contrast (ie AKI)
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Lower extremity dopplers
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              TTE: differentiate submassive vs low risk, chronic right sided failure (PAP>50 chronic)
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="line-height:107%">
             <span style="font-family:Palatino">
              Management
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="line-height:107%">
             <span style="font-family:Palatino">
              Acute:
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              ABCs: Provide necessary respiratory and hemodynamic support
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Initial AC:  If PE is highly probable (Wells score > 6) or moderately probable (Wells between 2-6, but workup will take > 4 hours) and bleeding risk is low, empirically start IV heparin drip, then establish a definitive diagnosis as per above (CTA PE).
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 IV heparin drip (EPIC order set): bolus (80 un/kg), then drip starting 18 unit/kg
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Enoxaparin (Lovenox): 1 mg/kg subQ q12h (*avoid in ESRD)
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Thrombolytics (tPA): Most effective within 24 hours, but effective up to 14 days. Use 100 mg of tPA over 2 hours, then resume heparin gtt. Attending/fellow level decision.
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Indications:
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li style="list-style-type:none">
           <ul style="list-style-type:disc">
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Massive PE: PE causing hypotension (shock)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Refractory hypoxia or respiratory failure requiring mechanical ventilation.
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  RV failure clinically or on echo (relative indication if not shock)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
           </ul>
          </li>
         </ul>
        </li>
       </ul>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              IVC filter (very uncommon): AC is contraindicated, bleeding risk unacceptably high, recurrent PE despite optimal AC
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Embolectomy: Catheter-directed or surgical
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Indicated for pt with submassive PE, pts with massive PE in whom thrombolytic therapy is contraindicated, or when thrombolytic therapy has failed
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
       </ul>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="line-height:107%">
             <span style="font-family:Palatino">
              Chronic:
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Long-term AC (DOAC is the mainstay of management)
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Apixaban (Eliquis): 10 mg BID x7 days
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Wingdings">
                à
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                5 mg BID
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li style="list-style-type:none">
             <ul style="list-style-type:disc">
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Can use in renal failure (do not dose reduce like for atrial fibrillation)
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
             </ul>
            </li>
           </ul>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Rivaroxaban (Xarelto): 15 mg BID x 21 days
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Wingdings">
                à
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                20 mg daily
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Needs to be taken with food, avoid with CrCl<30
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
           </ul>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Dabigatran (Pradaxa): 150 mg BID
                <b>
                 AFTER
                </b>
                5 days of parental therapy
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Warfarin (Coumadin): Goal INR 2-3, requires frequent monitoring
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Need to be bridged with enoxaparin or heparin gtt
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
           </ul>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Duration of Anticoagulation:
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Major reversible/transient risk factors (surgery, trauma): 3-6 months
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Idiopathic, unprovoked, or with less compelling risk factors: 12 months
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Major permanent risk factors (cancer, homozygote F5L or prothrombin gene mutation, APLS, protein C/S deficiencies, AT III deficiency): At least 1 year, preferably lifelong.
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Recurrent DVT/PE: lifelong
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
       </ul>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>